Epithelial-Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma

被引:11
|
作者
Uramoto, Hidetaka [1 ]
Iwata, Teruo
Onitsuka, Takamitsu
Shimokawa, Hidehiko
Hanagiri, Takeshi
Oyama, Tsunehiro [2 ]
机构
[1] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[2] Univ Occupat & Environm Hlth, Sch Med, Dept Environm Hlth, Kitakyushu, Fukuoka 8078555, Japan
关键词
EMT; lung cancer; adenocarcinoma; resistance; E-CADHERIN EXPRESSION; PROGNOSTIC-SIGNIFICANCE; GEFITINIB RESISTANCE; CANCER PATIENTS; CELL-LINES; SENSITIVITY; CARCINOMA; MUTATION; DETERMINES; ACTIVATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The epithelial to mesenchymal transition (EMT) may well play a part in determining the sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). However to date, no study has investigated the association between the EMT status and acquired resistance using cancer specimens. Patients and Methods: Immunohistochemical (IHC) staining was used to analyse the protein expression of epithelial and mesenchymal markers in tumour samples from lung adenocarcinoma patients. Mutations in the EGFR and K-ras gene were also examined. Results: All patients showed a positive expression of epithelial markers in sensitive tumours. Tumour in 4 (44.4%) out of 9 patients showed down-regulation of epithelial markers or up-regulation of mesenchymal markers. The change in the EMT status between pre-and post-treatment was shown in 2 cases each with and without the T790M mutation. Conclusion: EMT plays a role in approximately half of the cases of resistance to EGFR-TKI, independent of T790M mutation.
引用
收藏
页码:2513 / 2517
页数:5
相关论文
共 50 条
  • [1] Neuropilin-2 Promotes Acquired Resistance to EGFR-TKI Associated with the Epithelial-Mesenchymal Transition in Lung Cancer
    Nasarre, Patrick
    Nair-Menon, Joyce
    Dimou, Anastasios
    Yoshida, Takeshi
    Uramoto, Hidetaka
    Haura, Eric
    Gemmill, Robert M.
    Drabkin, Harry A.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S297 - S297
  • [2] Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition
    Wang, Cheng-Yi
    Lee, Meng-Hsuan
    Kao, Yu-Rung
    Hsiao, Shih-Hsin
    Hong, Shiao-Ya
    Wu, Cheng-Wen
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2021, 1868 (06):
  • [3] EXPRESSION OF NOTCH-1 IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA
    Xie, M.
    He, C. -S.
    Hou, J. -H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [4] Different first line EGFR-TKI regimen and the clearance of EGFR sensitive mutation in acquired EGFR-TKI resistant lung adenocarcinoma patients
    Zhuang, W.
    Xu, C.
    Wang, W.
    Song, Z.
    Zhu, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Fang, M.
    Chen, G.
    Lv, T.
    Song, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial-Mesenchymal Transition Status
    Yan, Rui
    Huang, Xuying
    Liu, Heshu
    Xiao, Zeru
    Liu, Jian
    An, Guangyu
    Ge, Yang
    BIOMEDICINES, 2023, 11 (05)
  • [6] Small cell transformation of lung adenocarcinoma in acquired resistance to EGFR-TKI
    So, Kwang Sup
    Choi, Yun Jung
    Kim, Sun Ye
    Choi, Chang-Min
    Lee, Jae Cheol
    Kim, Woo Sung
    Rho, Jin Kyung
    CANCER RESEARCH, 2013, 73 (08)
  • [7] Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer
    Chen, Junjie
    Shi, Lin
    Qian, Yao
    Jin, Yi
    Dong, Nian
    Chen, Chengshui
    Wang, Beibei
    JOURNAL OF THORACIC DISEASE, 2023, 15 (06) : 3359 - +
  • [8] SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION
    Suda, Kenichi
    Mizuuchi, Hiroshi
    Sato, Katsuaki
    Takemoto, Toshiki
    Iwasaki, Takuya
    Minami, Kenji
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S771 - S772
  • [9] Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
    Uramoto, Hidetaka
    Shimokawa, Hidehiko
    Hanagiri, Takeshi
    Kuwano, Michihiko
    Ono, Mayumi
    LUNG CANCER, 2011, 73 (03) : 361 - 365
  • [10] Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
    Lee, Jeong Eun
    Park, Hee Sun
    Lee, Dahye
    Yoo, Geon
    Kim, Tackhoon
    Jeon, Haeyon
    Yeo, Min-Kyung
    Lee, Choong-Sik
    Moon, Jae Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    Park, Dong Il
    Park, Yeon Hee
    Lee, Jae Cheol
    Oh, In-Jae
    Lim, Dae Sik
    Chung, Chaeuk
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (01) : 154 - 160